They Both Like These 2 ‘Strong Buy’ Stocks

Is there a right way to invest? Not really. Each person has their own individual style, but what ultimately matters are the results. This holds especially true in the realm of investing, where even the most successful stock pickers on Wall Street employ diverse strategies to achieve their goals. And what are those goals? Big returns, of course.

Take Billionaires Steve Cohen and Ken Griffin, for example. Both have had incredible careers, but each’s route to riches has been distinct. Griffin, who runs the Citadel hedge fund, adheres to quantitative investment methods, while Cohen, who leads the Point72 asset management firm, is famous for his high-risk/high-reward strategy.

That doesn’t mean their stock choices never cross paths. In fact, some specific equities make up a part of each’s respective portfolios. And if two investing gurus feel strongly about the same names, it’s only natural for investors to get curious as to why they’re both invested.

With this in mind, we used TipRanks’ database to find out if two stocks the billionaires recently added to their funds represent compelling plays. According to the platform, the analyst community believes they do, with both picks earning “Strong Buy” consensus ratings. Let’s check the details.

Humana Inc. (HUM)

Uncertain times make the healthcare segment an ideal destination, as the sector is seen as one touting defensive qualities able to withstand any harsh macro developments. So, it’s not that surprising to find both Cohen and Griffin invested in Humana, an American healthcare giant and a leading provider of health insurance plans and related services.

The Louisville, Kentucky-based firm is one of the largest managed care organizations in the U.S., offering a broad range of health insurance products, including individual and group plans, Medicare Advantage, and prescription drug plans. Humana serves millions of customers and boasts a market cap of over $64 billion.

Such a value proposition enabled the company to dial in a strong Q1 report. Revenue climbed by 11.6% year-over-year to $26.74 billion,…


Read More

Recommended For You

Leave a Reply

Your email address will not be published. Required fields are marked *